Add as a preferred source on GoogleBiogen Raises 2026 EPS Guidance Floor as Growth Portfolio Expands
The Growth Portfolio generated $1.26 billion, up 49% year over year, while multiple sclerosis product revenue fell 13% to $919 million.
Biogen raised the lower end of its full-year 2026 non-GAAP diluted earnings-per-share guidance after its Growth Portfolio expanded 49% in the third quarter, even as multiple sclerosis product revenue declined.
The company now expects non-GAAP diluted EPS of $12.20 to $13.00 for 2026. It lifted the lower end from $12.00 and kept the upper end at $13.00.
Revenue reached $2.804 billion, up 11% year over year. The Growth Portfolio generated $1.26 billion and drove double-digit revenue growth. The quarter included the first full quarter of Apellis products.
Multiple sclerosis product revenue fell 13% to $919 million from $1.062 billion in the year-earlier quarter.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.